(Q34393049)

English

Disposition of 5-aminosalicylic acid by olsalazine and three mesalazine preparations in patients with ulcerative colitis: comparison of intraluminal colonic concentrations, serum values, and urinary excretion

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

1 August 2017

Disposition of 5-aminosalicylic acid by olsalazine and three mesalazine preparations in patients with ulcerative colitis: comparison of intraluminal colonic concentrations, serum values, and urinary excretion (English)

1 reference

Europe PubMed Central

1 August 2017

0 references

ulcerative colitis

1 reference

based on heuristic

inferred from title

author name string

L Staerk Laursen

1

1 reference

Europe PubMed Central

1 August 2017

M Stokholm

2

1 reference

Europe PubMed Central

1 August 2017

K Bukhave

3

1 reference

Europe PubMed Central

1 August 2017

J Rask-Madsen

4

1 reference

Europe PubMed Central

1 August 2017

K Lauritsen

5

1 reference

Europe PubMed Central

1 August 2017

language of work or name

0 references

publication date

1 November 1990

1 reference

Europe PubMed Central

1 August 2017

1 reference

Europe PubMed Central

1 August 2017

31

1 reference

Europe PubMed Central

1 August 2017

1271-1276

1 reference

Europe PubMed Central

1 August 2017

11

1 reference

Europe PubMed Central

1 August 2017

An oral preparation to release drugs in the human colon

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1378698

6 July 2018

Incidence and prevalence of ulcerative colitis and Crohn's disease in the County of Copenhagen, 1962 to 1978.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1378698

6 July 2018

Kinetics of 5-aminosalicylic acid after jejunal instillation in man.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1378698

6 July 2018

Colonic release of 5-amino salicylic acid from an oral preparation in active ulcerative colitis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1378698

6 July 2018

Comparison of the absorption and metabolism of sulphasalazine and acrylic-coated 5-amino salicylic acid in normal subjects and patients with colitis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1378698

6 July 2018

Maintenance of remission in ulcerative colitis with 5-amino salicylic acid in high doses by mouth

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1378698

6 July 2018

Maintenance of remission in ulcerative colitis with oral preparation of 5-aminosalicylic acid

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1378698

6 July 2018

Will there be a next generation of sulfasalazine?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1378698

6 July 2018

Effect of sulphapyridine, 5-aminosalicylic acid, and placebo in patients with idiopathic proctitis: a study to determine the active therapeutic moiety of sulphasalazine

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1378698

6 July 2018

Optimum dose of sulphasalazine for maintenance treatment in ulcerative colitis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1378698

6 July 2018

Olsalazine in active ulcerative colitis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1378698

6 July 2018

Release of 5-aminosalicylic acid from Pentasa during normal and accelerated intestinal transit time

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1378698

6 July 2018

Metabolism and urinary excretion of 5-amino salicylic acid in healthy volunteers when given intravenously or released for absorption at different sites in the gastrointestinal tract

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1378698

6 July 2018

The pharmacokinetics of olsalazine sodium in healthy volunteers after a single i.v. dose and after oral doses with and without food.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1378698

6 July 2018

Nephrotic syndrome after treatment with 5-aminosalicylic acid

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1378698

6 July 2018

Double-blind comparison of 5-aminosalicylic acid and acetyl-5-aminosalicylic acid suppositories in patients with idiopathic proctitis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1378698

6 July 2018

Use of colonic eicosanoid concentrations as predictors of relapse in ulcerative colitis: double blind placebo controlled study on sulphasalazine maintenance treatment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1378698

6 July 2018

Comparison of delayed release 5 aminosalicylic acid (mesalazine) and sulphasalazine in the treatment of mild to moderate ulcerative colitis relapse

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1378698

6 July 2018

Controlled trial comparing olsalazine and sulphasalazine for the maintenance treatment of ulcerative colitis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1378698

6 July 2018

Comparison of delayed-release 5-aminosalicylic acid (mesalazine) and sulfasalazine as maintenance treatment for patients with ulcerative colitis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1378698

6 July 2018

Longterm olsalazine treatment: pharmacokinetics, tolerance and effects on local eicosanoid formation in ulcerative colitis and Crohn's colitis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1378698

6 July 2018

Comparative efficacy of coated, oral 5-aminosalicylic acid (Claversal) and sulphasalazine for maintaining remission of ulcerative colitis. International Study Group.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1378698

6 July 2018

An experiment to determine the active therapeutic moiety of sulphasalazine

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1378698

6 July 2018

Capacity-limited gut wall metabolism of 5-aminosalicylic acid, a therapeutically active metabolite of sulfasalazine, in rats

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1378698

6 July 2018

Nephrotoxic lesions from 5-aminosalicylic Acid.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1378698

27 October 2018

Treatment of ulcerative colitis with high-dose 5-aminosalicylic acid enemas

1 reference

https://pubmed.ncbi.nlm.nih.gov/2253912

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Double-blind comparison of slow-release 5-aminosalicylate and sulfasalazine in remission maintenance in ulcerative colitis

1 reference

https://pubmed.ncbi.nlm.nih.gov/2253912

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Gastrointestinal transit of an enteric-coated delayed-release 5-aminosalicylic acid tablet

1 reference

https://pubmed.ncbi.nlm.nih.gov/2253912

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Nephrotoxicity and Molecular Structure

1 reference

https://pubmed.ncbi.nlm.nih.gov/2253912

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Distribution studies of salicylazosulfapyridine and its metabolites

1 reference

https://pubmed.ncbi.nlm.nih.gov/2253912

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

5-aminosalicylic acid in a slow-release preparation: bioavailability, plasma level, and excretion in humans

1 reference

https://pubmed.ncbi.nlm.nih.gov/2253912

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study

1 reference

https://pubmed.ncbi.nlm.nih.gov/2253912

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Olsalazine sodium in the treatment of ulcerative colitis among patients intolerant of sulfasalazine. A prospective, randomized, placebo-controlled, double-blind, dose-ranging clinical trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/2253912

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A new slow-release form of 5-aminosalicylic acid for the oral treatment of inflammatory bowel disease. Biopharmaceutic and clinical pharmacokinetic characteristics

1 reference

https://pubmed.ncbi.nlm.nih.gov/2253912

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Colonic azodisalicylate metabolism determined by in vivo dialysis in healthy volunteers and patients with ulcerative colitis

1 reference

https://pubmed.ncbi.nlm.nih.gov/2253912

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Absorption, metabolism, and excretion of salicylazosulfapyridine in man

1 reference

https://pubmed.ncbi.nlm.nih.gov/2253912

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

IN VIVO DIALYSIS OF FAECES AS A METHOD OF STOOL ANALYSIS. I. TECHNIQUE AND RESULTS IN NORMAL SUBJECTS

1 reference

https://pubmed.ncbi.nlm.nih.gov/2253912

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Disposition of 5-aminosalicylic acid by 5-aminosalicylic acid-delivering compounds

1 reference

https://pubmed.ncbi.nlm.nih.gov/2253912

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

[Nephritis from 5-aminosalicylic acid]

1 reference

https://pubmed.ncbi.nlm.nih.gov/2253912

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Absorption and excretion of a single 1-g dose of azodisal sodium in subjects with ileostomy

1 reference

https://pubmed.ncbi.nlm.nih.gov/2253912

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1136/GUT.31.11.1271

1 reference

Europe PubMed Central

1 August 2017

1 reference

Europe PubMed Central

1 August 2017

1 reference

Europe PubMed Central

1 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34393049&oldid=1603448698"